This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Viral Infections  • Complementary and Alternative Medicine  • Immunotherapy  • Dermatology, Other  • Alert me on articles by topic

Rosamaria Corona, DSc,MD

Arch Dermatol. 2002;138:1599-1601.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Commentary on: Imiquimod for the treatment of genital warts: a quantitative systematic review
Moore RA, Edwards JE, Hopwood J, Hicks D
BMC Infect Dis. 2001;1:3

Question: In immunocompetent patients with external genital warts, what are the benefits and the harms of imiquimod therapy?

Data Sources: Studies were identified through a search of MEDLINE (1966-2000), the Cochrane Library (issue 3, 2000), and PubMed (December 15, 2000). Reference lists of review articles were searched for additional trials, and the manufacturers of 5% imiquimod cream were asked about clinical trials. Authors of articles were not contacted for unpublished reports or for additional information from published reports. No restrictions to language were made.

Study Selection: Studies were selected if they were randomized and double-blind and mentioned withdrawals and dropouts. Each of the 5 selected reports was scored for quality using a 3-item scale based on a score of 1 to . . . [Full Text of this Article]

Comment

Istituto Dermopatico dell'Immacolata, Rome, Italy